[CAS NO. 2211985-36-1] Nipocalimab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2211985-36-1]

Catalog

AS1024394

Brand

Arctom Scientific

CAS

2211985-36-1

DESCRIPTION [2211985-36-1]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Nipocalimab]

For research use only. We do not sell to patients.

Summary

Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor ( FcRn ) at both endosomal pH 6.0 and extracellular pH 7.6 ^[1] ^[2] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05221619	Janssen Research & Development, LLC	Warm Autoimmune Hemolytic Anemia
NCT05151692	Janssen Research & Development, LLC	Healthy	May 30, 2022	Phase 1
NCT03772587	Momenta Pharmaceuticals, Inc.	Generalized Myasthenia Gravis	April 10, 2019	Phase 2
NCT04882878	Janssen Research & Development, LLC	Systemic Lupus Erythematosus	August 20, 2021	Phase 2
NCT02828046	Momenta Pharmaceuticals, Inc.	Healthy Volunteers	May 9, 2016	Phase 1
NCT05379634	Janssen Research & Development, LLC	Myositis	July 5, 2022	Phase 2
NCT05327114	Janssen Research & Development, LLC	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	September 23, 2022	Phase 2\|Phase 3
NCT05265273	Janssen Research & Development, LLC	Myasthenia Gravis	July 20, 2022	Phase 2\|Phase 3
NCT04973566	Janssen Research & Development, LLC	Healthy	August 31, 2021	Phase 1
NCT03842189	Janssen Research & Development, LLC	Hemolytic Disease of the Fetus and Newborn	April 2, 2019	Phase 2
NCT04968912	Janssen Research & Development, LLC	Sjogren´s Syndrome	September 21, 2021	Phase 2
NCT04951622	Janssen Research & Development, LLC	Myasthenia Gravis	July 15, 2021	Phase 3
NCT04991753	Janssen Research & Development, LLC	Arthritis, Rheumatoid	October 14, 2021	Phase 2
NCT04883619	Janssen Research & Development, LLC	Lupus Nephritis	January 15, 2024	Phase 2
NCT03896295	Momenta Pharmaceuticals, Inc.	Generalized Myasthenia Gravis	August 6, 2019	Phase 2
NCT04848558	Janssen Research & Development, LLC	Healthy	May 25, 2021	Phase 1
NCT04119050	Janssen Research & Development, LLC	Warm Autoimmune Hemolytic Anemia	October 24, 2019	Phase 2\|Phase 3

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.